证券代码：603986 证券简称：兆易创新 公告编号：2025-051 兆易创新科技集团股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 兆易创新科技集团股份有限公司（以下简称"公司"）股票连续3个交易 日内日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的 有关规定，属于股票交易异常波动情形。 ? 经公司自查，并向控股股东、实际控制人书面询问，截至本公告披露日， 公司不存在影响上市公司股票交易异常波动的重大事项；不存在其他应披露未披 露的重大事项。公司目前生产经营正常，未发生重大变化。 ? 公司敬请广大投资者注意投资风险，理性决策、审慎投资。 一、股票交易异常波动的具体情况 公司股票交易于 2025 年 8 月 21 日、2025 年 8 月 22 日、2025 年 8 月 25 日 连续 3 个交易日内日收盘价格涨幅偏离值累计超过 20%，根据《上海证券交易所 交易规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 针对公 ...

证券代码：000609 证券简称：ST 中迪 公告编号：2025-109 北京中迪投资股份有限公司 关于公司股票交易异常波动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 北京中迪投资股份有限公司股票（股票代码：000609，证券简称：ST 中迪） 于 2025 年 8 月 20 日、8 月 21 日、8 月 22 日连续 3 个交易日收盘价格涨幅偏离 值累计达到 13.64%，根据《深圳证券交易所交易规则》的有关规定，属于股票 交易异常波动的情况。 二、公司核实情况说明 针对公司股票异常波动，公司对有关事项进行了核查，说明如下： 大影响的未公开重大信息。 大事项，或处于筹划阶段的重大事项。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据深交所《股票上市规则》规定 应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等；董事 会也未获悉本公司有根据深交所《股票上市规则》的规定应予以披露而未披露的、 对本公司股票及其衍生品种交易价格产生较大影响的信息；公司前期披露的信息， 本公司及董事 ...

Core Viewpoint - Shanghai Feilo Acoustics Co., Ltd. experienced a significant stock price fluctuation, with a cumulative increase of 20% over three consecutive trading days, prompting a warning to investors about potential market risks [1][2]. Group 1: Stock Trading Anomalies - The company's stock price increased by 20% over three trading days from August 20 to August 22, 2025, which is classified as an abnormal trading fluctuation according to Shanghai Stock Exchange rules [2]. - On August 22, 2025, the stock's turnover rate reached 7.50%, and the price fluctuation was 10.85%, indicating a potential for irrational speculation [1][2]. Group 2: Company Operations and Disclosures - The company confirmed that its production and operations are normal, with no significant changes expected in the internal or external business environment [2][3]. - There are no undisclosed significant matters related to the company, its controlling shareholder, or actual controllers, including major asset restructuring, share issuance, or strategic investments [2][3]. Group 3: Market Valuation Concerns - As of August 21, 2025, the rolling price-to-earnings (P/E) ratio for the company was 615.46, significantly higher than the industry average P/E ratio of 21.33 for the electrical machinery and equipment manufacturing sector [2][4]. - The company urges investors to be cautious due to the high valuation compared to industry standards [4].

Core Viewpoint - Ningbo Shimao Energy Co., Ltd. experienced a significant stock price fluctuation, with a cumulative increase of 20% over three consecutive trading days, prompting a disclosure regarding abnormal trading conditions [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price increased by a cumulative 20% from August 19 to August 21, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [2][4]. - The trading volume over the three days reached a turnover rate of 22.07%, exceeding the normal trading rate [2][4]. Group 2: Company Operations and Financial Performance - As of the announcement date, the company's main business operations and external environment have not undergone significant changes compared to previous disclosures [5]. - For the first quarter of 2025, the company reported a revenue of 77.27 million yuan, a year-on-year decrease of 16.14%, and a net profit of 21.85 million yuan, down 35.66% year-on-year, primarily due to a decline in heat sales and an increase in fixed asset depreciation [2][5]. Group 3: Market Position and Valuation - The company's price-to-earnings (P/E) ratio stands at 25.03 and the price-to-book (P/B) ratio at 3.27, both of which are higher than the industry averages of 18.37 for P/E and 1.6 for P/B [2][7].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days from August 18 to August 20, 2025, indicating abnormal trading activity [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price closed at 33.11 yuan per share as of August 20, 2025, with a recent cumulative increase that surpasses most peers in the industry and the Shanghai Composite Index [2][9]. - The rolling price-to-earnings (P/E) ratio for the company is reported at 338.72, significantly deviating from the industry average P/E ratio of 32.11 for the pharmaceutical manufacturing sector [2][9]. Group 2: Company Operations and Confirmations - The company conducted a self-examination and confirmed that its daily operations remain normal, with no significant changes or major events affecting its business [4][5]. - There are no undisclosed significant matters or ongoing major asset restructuring, share issuance, or other substantial corporate actions as of the announcement date [5][8]. Group 3: Market and Media Influence - The company has not identified any media reports or market rumors that could have significantly impacted its stock price, nor any leaks of undisclosed major information by company personnel [6][7].

Core Viewpoint - The stock of Taihao Technology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days from August 18 to August 20, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [2][4]. Group 1: Stock Trading Abnormality - The stock price deviation reached a cumulative increase of 20% over three consecutive trading days [2][4]. - The company confirmed that its main business and production operations are normal, with no significant changes in market conditions or industry policies [2][5]. Group 2: Company Verification and Major Events - The company is planning to acquire a 27.46% stake in its subsidiary, Taihao Military Industry, through a share issuance [3][7]. - The first major shareholder, Tongfang Co., Ltd., confirmed that there are no undisclosed significant matters related to the company [7][12]. Group 3: Media Reports and Market Rumors - The company has not identified any media reports or market rumors that could significantly impact its stock price [8][9]. Group 4: Board of Directors Statement - The board of directors confirmed that there are no undisclosed matters that should be disclosed according to the relevant regulations of the Shanghai Stock Exchange [12].

Core Viewpoint - The company, Yazhen Home Co., Ltd., has experienced a significant stock price fluctuation, leading to a temporary suspension of trading to protect investor interests. The stock will resume trading on August 21, 2025, after a thorough review of its trading activities and financial performance [2][3][13]. Group 1: Stock Trading and Suspension - The company's stock price increased by 33.92% from July 30 to August 6, 2025, significantly deviating from the Shanghai Composite Index and the furniture manufacturing industry [2][3]. - The stock was suspended from trading on August 7, 2025, for a period not exceeding 10 trading days, to conduct a review of the trading situation [3][13]. - The stock will resume trading on August 21, 2025, following the completion of the review [3][13]. Group 2: Financial Performance - For the fiscal year 2024, the company reported total revenue of 202.40 million yuan, with a net loss attributable to shareholders of 116.96 million yuan [4][9]. - The company expects a net loss for the first half of 2025 to be between 39.50 million yuan and 33.00 million yuan [4][9]. - The company has been placed under delisting risk warning since May 6, 2025, due to its financial performance [4][9]. Group 3: Acquisition and Business Development - The company plans to acquire 51% of Guangxi Zirconium Industry Technology Co., Ltd. from Hainan Zirconium Titanium Resources Holdings Group Co., Ltd. for 55.45 million yuan [5][15]. - As of August 20, 2025, the acquisition has been completed, and Guangxi Zirconium has become a subsidiary of the company [5][16]. - The company has initiated the pledge procedures for the acquired shares, which have been successfully registered [18].

登录新浪财经APP 搜索【信披】查看更多考评等级 安徽中电鑫龙科技股份有限公司（以下简称"公司"或"本公司"）股票交易价格连续3个交易日（2025年8 月15日、8月18日、8月19日）收盘价格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规则》等 有关规定，属于股票交易异常波动的情形。 二、公司关注、核实情况说明 针对公司股票异常波动，公司董事会对有关事项进行了核实，有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司目前经营情况正常，不存在内外部经营环境发生重大变化的情形； 3、公司及控股股东、实际控制人不存在关于公司的应披露而未披露的重大事项，或处于筹划阶段的重 大事项； 4、经核查，控股股东、实际控制人在公司股票交易异常波动期间不存在买卖公司股票的行为； 5、经自查，公司不存在违反公平信息披露规定的其他情形。 公司董事会全体董事保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动情况 公司董事会确认，公司目前没有根据《深圳证券交易所股票上市规则》等有关规定应予以披露而未披露 的事项或与该事项有关的筹划、商谈、意向、协议等；董事会也未获 ...

Core Viewpoint - Oulin Bio (688319) experienced a significant stock price increase, with a cumulative rise of over 30% in three consecutive trading days, leading to a classification of abnormal trading activity [1] Company Summary - Oulin Bio confirmed that its daily operations are normal and there have been no significant changes in its business [1] - The company conducted inquiries with its controlling shareholder and actual controller, confirming that there are no undisclosed major information as of the announcement date [1] - The recent stock price increase of Oulin Bio has outpaced most of its industry peers and the Shanghai Composite Index, indicating a potential short-term market overheating risk [1]

Core Viewpoint - The stock price of Nord New Materials Co., Ltd. experienced an abnormal fluctuation, with a cumulative increase of 20% over three consecutive trading days in August 2025, prompting regulatory scrutiny [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price rose by a cumulative 20% on August 15, 18, and 19, 2025, indicating abnormal trading behavior as per Shanghai Stock Exchange regulations [2][4]. - The stock price increased by 33.18% from August 14 to August 19, 2025, while the relevant industry index only rose by 3.99% during the same period [8]. Group 2: Financial Performance - In 2024, the company reported a revenue of 5.277 billion, a year-on-year increase of 15.44%, but incurred a net loss of 352 million [5]. - For the first quarter of 2025, the company achieved a revenue of 1.409 billion but reported a net loss of 38 million [5]. - Preliminary estimates suggest a net loss of approximately 70 million for the first half of 2025, with a net loss of around 82 million after excluding non-recurring items [5]. Group 3: Regulatory Issues - The company and its chairman, along with other executives, received a notice from the China Securities Regulatory Commission regarding suspected violations of information disclosure laws [3][9]. - The company is cooperating with the investigation and has not yet received a conclusive opinion on the matter [9]. Group 4: Management Assurance - The board of directors confirmed that there are no undisclosed significant matters that could affect stock trading, and all required disclosures have been made [12].